Ceylon Cinnamon vs. Cassia: Why the Difference Matters

Ceylon Cinnamon: What "True Cinnamon" Actually Means

Ceylon cinnamon is the dried inner bark of *Cinnamomum verum*, a tree native to Sri Lanka. It is also called "true cinnamon." It differs from common cassia cinnamon on two dimensions: coumarin content and flavor. It is sold as ground spice, rolled sticks called quills, capsules, and extracts.

Cinnamomum is a genus of evergreen trees with four commercially relevant species: verum (Ceylon), cassia (Chinese), burmannii (Indonesian), and loureiroi (Vietnamese). The latter three are grouped together as "cassia" in most consumer contexts. Cassia varieties dominate the US spice market. The Ceylon-vs-cassia distinction matters most because of coumarin, a compound with very different concentrations across species.

Chemistry and structure

Cinnamaldehyde is the dominant bioactive in cinnamon, making up roughly 70–90% of its volatile oil. It drives the characteristic flavor and is central to the proposed glycemic mechanism. Cinnamon has been shown to delay gastric emptying in healthy adults, one of several proposed pathways. Coumarin is the second-order compound, and the one that varies dramatically by species. Cassia contains roughly 1% coumarin by mass. Coumarin levels in cassia have been confirmed across multiple markets, and retail ground cassia consistently tests at high coumarin levels. Ceylon contains roughly 0.004% coumarin, approximately a 250-fold difference. Coumarin content varies significantly across Cinnamomum species, including low-coumarin alternatives like Cinnamomum osmophloeum. Other bioactives include cinnamic acid and proanthocyanidins.

Source and history of use

Ceylon cinnamon has been cultivated in Sri Lanka for over 2,000 years. It was the primary cinnamon in European trade through the colonial era. Cassia varieties (Chinese, Vietnamese, Indonesian) now dominate the modern US market. They are cheaper to produce and carry a stronger, more pungent flavor. The "true cinnamon" branding for Ceylon is largely a post-2000 consumer-education response. It emerged alongside the coumarin-toxicity literature, particularly evidence linking high-dose cinnamon-containing traditional medicines to hepatotoxicity.

How Cinnamon Works in Your Body

The proposed primary mechanism is glycemic. Cinnamaldehyde and related compounds have been shown in cell-line and animal models to inhibit alpha-glucosidase and alpha-amylase, the gut enzymes that break down dietary carbohydrates. They also appear to potentiate insulin signaling at the receptor level. Neither mechanism is fully settled in humans.

Mechanism of action

Alpha-glucosidase and alpha-amylase are the enzymes that convert complex carbohydrates into absorbable sugars in the gut. Cinnamaldehyde and proanthocyanidins are proposed to inhibit both, slowing the rate at which glucose enters the bloodstream after a meal. Pharmacological alpha-glucosidase inhibitors are an established class of prescription antidiabetic drugs; cinnamon's in-vitro alpha-glucosidase inhibition does not make it equivalent to those medications. An RCT in healthy adults demonstrated that cinnamon delays gastric emptying, which would independently blunt postprandial glucose spikes. Additional proposed mechanisms include insulin-receptor potentiation and GLUT4 translocation, a process where glucose transporters move to the cell surface, allowing glucose uptake without additional insulin. The relative contribution of each mechanism in living humans is not settled. For lipids, cinnamon's effects on LDL-C and triglycerides are smaller and more variable than its glycemic effects. The broader cardiometabolic picture remains inconsistent across meta-analyses.

Pharmacokinetics

Cinnamaldehyde is rapidly absorbed after oral intake. It is metabolized in the liver: cinnamaldehyde converts to cinnamic acid, then to hippuric acid, and is excreted in urine. The half-life is short, measured in hours. Coumarin from cassia is also rapidly absorbed. A four-way crossover study in humans confirmed that coumarin bioavailability from cinnamon is comparable to isolated coumarin. Coumarin hepatotoxicity is dose-dependent and idiosyncratic. That is the basis for the European Food Safety Authority (EFSA) tolerable daily intake (TDI) of 0.1 mg/kg body weight. The pharmacokinetic distinction between Ceylon and cassia is small for cinnamaldehyde but large for coumarin. At 6 g/day of cassia for four weeks, total coumarin intake can exceed the EFSA TDI. At the same dose of Ceylon, it does not.

Where the Evidence Lands on Each Claim

The claims behind cinnamon span fasting glucose, HbA1c in type 2 diabetes (T2D), lipid markers, and whether Ceylon cinnamon is safer than cassia at daily supplemental doses.

Cinnamon may support healthy fasting glucose levels: Moderate

An updated dose-response meta-analysis found modest reductions in fasting glucose in T2D. Earlier meta-analyses corroborated this direction of effect. The original Cochrane review found the evidence insufficient at the time of its publication, an important historical anchor. A GRADE-assessed systematic review represents the highest-quality synthesis on cardiovascular risk factors including fasting glucose. A meta-analysis specifically on Cassia bark found modest glucose-lowering effects in T2D, relevant because most trials used cassia, not Ceylon. Effect sizes across the literature are modest and heterogeneous.

Cinnamon may support HbA1c reduction in T2D: Moderate

The most current systematic review and meta-analysis found modest HbA1c reductions in T2D. A dose-response meta-analysis of cinnamon's effects on glycolipid metabolism and a separate meta-analysis on glycolipid metabolism in T2D point in the same direction. An RCT using aqueous cinnamon extract specifically documented postprandial glucose effects. Effects are inconsistent across trials. Cinnamon is not a substitute for clinically indicated glucose-lowering therapy.

Cinnamon supports lipid markers (LDL-C, triglycerides): Limited

An umbrella meta-analysis on cinnamon's effects on lipid profile, oxidative stress, and inflammation found mixed results across endpoints with smaller effect sizes than the glycemic data. A meta-analysis of cinnamon supplementation found inconsistent lipid-profile effects, and an earlier meta-analysis on blood lipid concentrations reflects the same inconsistency. The GRADE-assessed cardiovascular risk factor review is the most current synthesis on this question. The lipid effect is plausible but not reliably demonstrated.

Ceylon cinnamon is safer than cassia for daily supplemental use: Strong

NMR quantification of commercially available cinnamon barks confirms a ~250-fold coumarin difference between Ceylon and cassia. Human case evidence documents hepatotoxicity from cumulative coumarin intake in cinnamon-containing traditional medicines. Coumarin from cinnamon is bioavailable at levels comparable to isolated coumarin, making the species distinction clinically meaningful. The EFSA TDI of 0.1 mg/kg body weight is the regulatory anchor. A recent review explicitly synthesizing efficacy and safety of cinnamon derivatives reinforces the Ceylon safety advantage for diabetes. For daily multi-gram supplementation, Ceylon is the variant the literature points to on safety grounds.

What cinnamon is not shown to do: Cinnamon does not prevent or treat type 2 diabetes. It does not meaningfully reduce body weight, cure cancer, or replace any prescribed glucose-lowering medication. The accurate framing is that cinnamon may support healthy fasting glucose levels already in or near the normal range, not that it corrects significantly elevated glycemia on its own.

Forms, Variants, and What to Look for on the Label

For cinnamon, the consequential question is not capsule vs. powder. It is Ceylon vs. cassia. Ground cinnamon, sticks, capsules, and aqueous extracts all carry the cinnamaldehyde and coumarin content of their source species. Form matters less than species.

• Ceylon cinnamon (Cinnamomum verum), ground or in capsules. Approximately 0.004% coumarin; milder, more complex flavor; multi-layered quill appearance distinguishes the stick form from cassia. Look for a certificate of analysis (COA) with species verification. Mislabeling cassia as Ceylon is a documented problem.
• Cassia cinnamon (Cinnamomum cassia / burmannii / loureiroi), ground or in capsules. Approximately 1% coumarin; stronger, more familiar grocery-store flavor; single-curl stick. Adequate for culinary use. At high daily supplemental doses, coumarin exposure can exceed the EFSA TDI.
• Aqueous cinnamon extract. Water extracts coumarin less efficiently than ethanol. Some glycemic trial protocols specifically use aqueous extracts to reduce coumarin exposure while preserving the cinnamaldehyde fraction.
• Cinnamon-derived cinnamaldehyde isolates. Separates the proposed active glycemic compound from the coumarin question entirely. An emerging supplement category with limited long-term human safety data.

Third-party testing programs (USP, NSF International, ConsumerLab) cover relatively few cinnamon products. When evaluating a supplement, look for species verification on the COA. Ceylon vs. cassia mislabeling is a known issue in the commercial market. Heavy-metal testing and coumarin quantification are additional quality markers worth requesting.

"True cinnamon" is not a regulated term. The only reliable verification is the Latin species name Cinnamomum verum on the label or COA. Marketing language alone is not sufficient.

Regulatory Status (as of May 2026)

Both Ceylon and cassia cinnamon are GRAS (generally recognized as safe) listed for culinary use in the United States. As dietary supplements, neither is FDA-approved for any indication. The EFSA TDI for coumarin (0.1 mg/kg body weight per day) is the primary regulatory anchor for the cassia daily-supplemental-dose concern. At typical supplemental doses of cassia, coumarin intake can approach or exceed this threshold. No new dietary ingredient (NDI) filing is required for either species under current DSHEA rules. FDA enforcement actions against cinnamon supplements have historically targeted products making explicit disease-treatment claims for diabetes. Separately, FDA recall actions on ground cinnamon products for lead contamination (active in some product categories in 2024 and 2025) reflect a sourcing and manufacturing quality issue, not a species-specific one.

Safety: The Coumarin Question First

Large-scale safety data on supplemental cinnamon is limited. The coumarin-hepatotoxicity question dominates the cassia safety profile. Ceylon's safety profile, by contrast, is broadly similar to other GRAS spices at typical use levels.

Reported side effects

The adverse event profile in cinnamon RCTs is dominated by mild gastrointestinal upset (loose stool and indigestion) at doses of 3 g/day or higher. Allergic contact stomatitis (mouth irritation) is rare and not species-specific. At high cumulative supplemental doses of cassia, coumarin-related hepatotoxicity has been documented in clinical case-report literature. Case-driven evidence from cinnamon-containing traditional medicines documents liver injury from cumulative coumarin intake. A synthesis of efficacy and safety data for cinnamon derivatives in diabetes reinforces this concern at high cassia doses. Lead contamination is a sourcing and manufacturing quality issue. Recent FDA recall actions illustrate the source-specific risk rather than a species-inherent one. Studies and case reports have documented these effects; neither "safe" nor "dangerous" is an accurate blanket characterization.

Drug interactions

• Anticoagulants (warfarin, DOACs): Moderate (cassia) / Minor (Ceylon). Coumarin is structurally related to anticoagulant precursors. Cassia at high daily doses is the relevant concern. Coumarin from cinnamon is bioavailable at clinically meaningful levels. Ceylon's negligible coumarin content may substantially reduces this interaction risk, but should be discussed with a clinician before commencing.
• Insulin and oral hypoglycemics (sulfonylureas, GLP-1 receptor agonists): Moderate. Additive hypoglycemia is plausible at supplemental doses. The glycemic-trial literature provides the mechanistic basis for additive hypoglycemia. Glucose monitoring is appropriate if combined with prescribed therapy.
• Hepatically metabolized medications (CYP3A4 substrates): Minor. Cinnamon modulates several CYP enzymes in vitro. Clinical significance at culinary doses is low; at supplemental doses, it is uncertain.
• Iron supplements: Minor. Polyphenol content may reduce non-heme iron absorption. Separating dosing by two hours reduces this interaction.

Pregnancy, breastfeeding, and organ-function callouts

Culinary-dose cinnamon has a long history of use in pregnancy. Supplemental doses should be avoided during pregnancy and breastfeeding without obstetric sign-off; no controlled human safety data exists at supplemental doses. For people with hepatic impairment, cassia at supplemental doses warrants particular caution given the coumarin-hepatotoxicity literature. Ceylon is the variant of choice if cinnamon supplementation is being considered in this population. No specific contraindication exists for renal impairment at typical doses. In the diabetes population (the group most represented in the glycemic trial literature), clinician supervision is appropriate when cinnamon supplementation is combined with prescribed glucose-lowering therapy.

Who Should Avoid Supplemental Cinnamon (and Talk to a Clinician First)

Supplemental cinnamon is not appropriate for everyone. The following groups warrant particular caution or should avoid it without clinician guidance.

• Pregnant or breastfeeding individuals: no controlled human safety data at supplemental doses.
• Anyone using cassia at multi-gram daily doses for more than four weeks without species verification: coumarin exposure may exceed the EFSA TDI; switching to verified Ceylon is the appropriate step if continued supplementation is desired.
• People with hepatic impairment or active liver disease: particular caution with cassia at any supplemental dose.
• People on anticoagulants (warfarin, DOACs): cassia is contraindicated at supplemental doses; Ceylon is less restrictive but warrants clinician awareness.
• People with diabetes on insulin or sulfonylureas: additive hypoglycemia is possible; clinician-guided glucose monitoring is appropriate if combined.
• Children: supplemental doses are not characterized in pediatric populations; culinary doses are uncontroversial.

If any of the above apply, do not start this supplement without speaking to a clinician familiar with your full medication list and biomarkers.

Ceylon vs. Cassia: A Direct Side-by-Side for You

The practical question is which species, at what dose, serves which goal, and where the safety line sits for each.

• Source and chemistry. Ceylon: dried inner bark of Cinnamomum verum, native to Sri Lanka; approximately 0.004% coumarin. Cassia: dried bark of C. cassia / burmannii / loureiroi, predominantly from China, Indonesia, and Vietnam; approximately 1% coumarin.
• Bioavailability. Ceylon: cinnamaldehyde absorbed rapidly; minimal coumarin to be absorbed. Cassia: cinnamaldehyde absorbed rapidly; coumarin is bioavailable at levels comparable to isolated coumarin.
• Strongest evidence. Ceylon: smaller sub-group analyses within glycemic meta-analyses. Cassia: most direct RCT and meta-analytic evidence. A meta-analysis specifically on Cassia bark in T2D documented glucose-lowering effects, and an updated dose-response meta-analysis across approximately 1,098 participants found modest fasting-glucose reductions at doses of 120 mg to 6 g/day over 4 to 18 weeks.
• Studied dose range. Ceylon: 120 mg to 6 g/day. Cassia: same range, but daily cassia at the upper end exceeds the EFSA coumarin TDI.
• Key safety differences. Ceylon: minimal coumarin-related hepatotoxicity risk. Cassia: documented coumarin hepatotoxicity at high daily intake.
• Cost (relative). Ceylon: $$. Cassia: $.
• Regulatory status. Both: GRAS for culinary use, regulated as dietary supplements under DSHEA, not FDA-approved for any therapeutic indication. Cassia carries the EFSA coumarin-TDI constraint at supplemental daily intake.

For someone whose primary interest is daily multi-gram supplementation over months, the EFSA coumarin TDI is more comfortably stayed below with Ceylon than with cassia. The coumarin difference is not theoretical. It is quantified, bioavailable, and linked to documented liver injury at high cassia doses. For someone whose primary interest is replicating the trial-literature efficacy at lower doses (1 to 2 g/day) for limited windows, cassia is the variant most studies actually used. Study heterogeneity in cinnamon trials is substantial across published RCTs, and results should not be extrapolated across dose ranges or durations without caution. The biomarker that would actually answer this question for a given individual is HbA1c, or fasting insulin if the primary interest is insulin sensitivity.

The Biomarkers That Tell You Whether Your Cinnamon Is Doing Anything

The proposed glycemic mechanism connects directly to specific bloodwork. It is not possible to tell whether cinnamon is doing anything from how one feels. A comparable Day 0 and 8-to-12-week panel makes any change interpretable.

• HbA1c: Three-month average glycemia. If cinnamon is doing anything via the alpha-glucosidase or insulin-signaling pathway, it shows here over 12 weeks.
• Fasting insulin: Insulin sensitivity marker. The readout most likely to move if the insulin-receptor potentiation mechanism is the dominant lever in a given individual.
• Fasting glucose: Faster-moving glucose readout. Can shift within 4 to 8 weeks and provides an earlier signal than HbA1c.
• LDL-C: Standard lipid readout. Lipid effects in the meta-analytic literature are smaller and less consistent than glycemic effects; LDL-C is the conventional starting point.
• ApoB: Atherogenic-particle count. The higher-resolution cardiometabolic readout when tracking lipid effects; captures small, dense LDL particles that LDL-C alone can miss.

When Cinnamon Is Not the Right Starting Point for You

If the reason for reaching for cinnamon is a suspicion of diabetes, a significantly elevated fasting glucose, or an HbA1c already in the prediabetes or diabetes range, that clinical picture deserves a primary-care metabolic workup, not supplement self-treatment. Comparative evidence across herbal options for glycemic control in T2D consistently shows no herb replaces glucose-lowering therapy. Cinnamon is not a substitute for that conversation.

Measuring biology before acting on it is the foundation of Superpower's approach to preventive health. A measured HbA1c baseline is the starting point, whether or not Ceylon cinnamon turns out to be the right tool for what you are trying to address.